Patents by Inventor Fernando G. Vieira

Fernando G. Vieira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS
    Publication number: 20240043549
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: June 26, 2023
    Publication date: February 8, 2024
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS
    Publication number: 20240016879
    Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: April 19, 2023
    Publication date: January 18, 2024
    Inventors: Steven Perrin, Fernando G. Vieira, Alan Gill, Theo Hatzipetros, Kyle Denton, Matvey Lukashev
  • Inhibition of dipeptide repeat proteins
    Patent number: 11857534
    Abstract: Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: January 2, 2024
    Assignee: ALS Therapy Development Institute
    Inventors: Fernando G. Vieira, Alan Premasiri, Anna Gill
  • Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders
    Patent number: 11692040
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: July 4, 2023
    Assignee: ALS THERAPY DEVELOPMENT INSTITUTE
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Copper complexes for treatment of neurodegenerative disorders
    Patent number: 11660324
    Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: May 30, 2023
    Assignee: ALS THERAPY DEVELOPMENT INSTITUTE
    Inventors: Steven Perrin, Fernando G. Vieira, Alan Gill, Theo Hatzipetros, Kyle Denton, Matvey Lukashev
  • Inhibition of dipeptide repeat proteins
    Patent number: 11607402
    Abstract: Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: March 21, 2023
    Assignee: ALS Therapy Development Institute
    Inventors: Fernando G. Vieira, Alan Premasiri, Anna Gill
  • INHIBITION OF DIPEPTIDE REPEAT PROTEINS
    Publication number: 20220142974
    Abstract: Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).
    Type: Application
    Filed: January 26, 2022
    Publication date: May 12, 2022
    Inventors: Fernando G. VIEIRA, Alan PREMASIRI, Anna GILL
  • ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS
    Publication number: 20210269538
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: May 17, 2021
    Publication date: September 2, 2021
    Applicant: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Anti-CD40L antibodies
    Patent number: 11014990
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: May 25, 2021
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS
    Publication number: 20210038676
    Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: July 24, 2020
    Publication date: February 11, 2021
    Inventors: Steven Perrin, Fernando G. Vieira, Alan Gill, Theo Hatzipetros, Kyle Denton, Matvey Lukashev
  • INHIBITION OF DIPEPTIDE REPEAT PROTEINS
    Publication number: 20200405689
    Abstract: Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).
    Type: Application
    Filed: June 8, 2020
    Publication date: December 31, 2020
    Inventors: Fernando G. VIEIRA, Alan PREMASIRI, Anna GILL
  • ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS
    Publication number: 20200277391
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: May 13, 2020
    Publication date: September 3, 2020
    Applicant: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodies
    Patent number: 10683356
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 16, 2020
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS
    Publication number: 20190092868
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 28, 2019
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Anti-CD40L antibodies
    Patent number: 10106618
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: October 23, 2018
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS
    Publication number: 20170342158
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 30, 2017
    Applicant: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira